MycoTechnology's Zukora Brings Honey Truffle Sweet Protein to the U.S. Market
- Gauri Khanna
- 6 days ago
- 3 min read
Too long to read? Go for the highlights below.
MycoTechnology has achieved self-affirmed GRAS status for Zukora, its fermentation-derived sweet protein, clearing the way for commercial sales in the United States.
Derived from Hungarian honey truffles, Zukora is up to 2,500 times sweeter than sugar, fully digestible, and reported to be gut-microbiome friendly.
The company has scaled production from pilot batches to full manufacturing volumes at its 86,000 sq ft facility in Aurora, Colorado.
From Fungal Curiosity to Commercial Sweetener
Deep in the flavour labs of Colorado, a protein sourced from an obscure Eastern European truffle is quietly reshaping how food manufacturers think about sugar reduction. MycoTechnology, a food ingredient company based in Aurora, has announced that its honey truffle sweet protein, marketed under the brand name Zukora, has achieved self-affirmed Generally Recognised as Safe (GRAS) status in the United States and is now available at commercial scale.
GRAS status, in the American regulatory system, is the threshold that permits an ingredient to be used in food and beverages. Self-affirmed GRAS means an independent panel of scientific experts has reviewed the safety evidence and found it satisfactory: a rigorous, if industry-led, process. MycoTechnology has also submitted a formal dossier to the U.S. Food and Drug Administration for independent review, which typically takes between nine and eighteen months to conclude.
The ingredient originates from Mattirolomyces terfezioides, the Hungarian honey truffle, which produces a naturally sweet protein. MycoTechnology isolated the gene responsible for this sweetness and inserted it into a yeast host, Komagataella phaffii, which then expresses the protein during fermentation. This approach, known as precision fermentation, allows the company to produce the ingredient at scale without relying on truffle harvests. Precision fermentation has attracted growing investment across the alternative protein sector, as it offers a route to natural compounds that would otherwise be difficult or expensive to source.
A Sweetener Built for the Current Moment
The timing is not accidental. According to a 2025 survey by the International Food Information Council, three in four Americans are actively trying to limit or avoid added sugar, yet taste remains the primary driver of food and beverage purchasing decisions. This tension, between health intentions and palatability, is precisely the gap Zukora is designed to fill.
The protein is reported to carry no bitter aftertaste or off-notes, a persistent problem with many existing high-intensity sweeteners such as stevia or monk fruit extracts. It is also fully digestible, breaking down in the gastrointestinal tract into common amino acids, and preliminary studies suggest it is friendly to the gut microbiome. These properties position Zukora favourably within the growing consumer interest in gut health, partly driven by the mainstream adoption of GLP-1 weight-management drugs such as Ozempic.
At up to 2,500 times the sweetness of sucrose, meaning a single teaspoon of Zukora can theoretically replace around 216 teaspoons of sugar, the ingredient sits at the more potent end of natural sweetener options. The cost-in-use is described as competitive with sugar, with further economies of scale anticipated as production volumes grow.
Scaling Up and Looking Ahead
MycoTechnology, which has raised $220 million in total funding, is not new to mycelium-derived food ingredients. The company previously commercialised two flavour-modulating products (ClearIQ, which reduces bitter and astringent notes in food, and ClearHT, which enhances desirable flavours) both derived from culinary mushroom mycelium. Regulatory approval for novel fungal food ingredients has become an increasingly active frontier as the sector matures.
Target applications for Zukora span functional beverages, protein and nutrition bars, and confectionery including chocolate and chewing gum. The company's sales team reports active engagement with food and beverage manufacturers on reformulation projects, though commercial product launches remain subject to each manufacturer's own development timelines.
MycoTechnology enters a nascent but increasingly competitive sweet protein category. Amai Proteins received FDA clearance for its monellin-based Sweelin just weeks prior, and Oobli holds FDA approval for three sweet proteins. Whether truffle-derived fermentation can carve out a durable position in this market will depend as much on taste performance in finished products as on the scientific credentials now firmly in place.